Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring EGFR mutation [0.03%]
表皮生长因子受体酪氨酸激酶抑制剂辅助治疗伴有EGFR突变的N2期完全切除非小细胞肺癌
Yinyin Xue,Qiang Wu,Wen Li et al.
Yinyin Xue et al.
Background: Adjuvant therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is effective and safe for patients with completely resected non-small cell lung cancer (NSCLC) with EGFR mutations,...
Annual progress in transbronchial diagnosis and treatment of pulmonary malignant tumors [2025]: a narrative review [0.03%]
经支气管诊断和治疗肺恶性肿瘤的年度进展（2025）：综述性文章
Ao Sun,Dongyang Xu,Jiayuan Sun
Ao Sun
Background and objective: The rapid advancement of transbronchial endoscopic interventional techniques is profoundly transforming the diagnostic and therapeutic landscape of pulmonary malignant tumors. This article review...
Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study [0.03%]
基于临床病理和影像学特征的ROS1重排在肺腺癌预后价值的队列研究
Yi Liu,Zelin Ma,Shuxiao Ma et al.
Yi Liu et al.
Background: The prognostic significance of ROS1 rearrangement in lung adenocarcinoma (LUAD) remains a subject of debate. This study systematically evaluated the clinicopathologic characteristics and prognostic impact of R...
Case report: first-line lorlatinib in metastatic lung adenocarcinoma with a novel WIPF1-ALK and EML4-ALK dual fusion [0.03%]
病例报告：一线 Lorlatinib 治疗新型 WIPF1-ALK 和 EML4-ALK 双融合突变的晚期肺腺癌
Sili Wang,Xinxin Chen,Yangyang Ma et al.
Sili Wang et al.
Background: The clinical management of non-small cell lung cancer (NSCLC) harboring rare anaplastic lymphoma kinase (ALK) fusion variants and complex molecular profiles remains challenging. Herein, we report, for the firs...
Challenges for first-line therapy in elderly patients with metastatic non-small cell lung cancer [0.03%]
老年患者晚期非小细胞肺癌一线治疗的挑战
Thierry Landre,Lorenzo Tommasi,Christos Chouaïd
Thierry Landre
Macrophages in lung cancer: principal factors, regulatory mechanisms, and therapeutic opportunities: a narrative review [0.03%]
肺癌中的巨噬细胞：主要因素、调节机制和治疗机会：叙述性综述
Yuanjing Tian,Yanan Wu,Song Mi et al.
Yuanjing Tian et al.
Background and objective: Lung cancer is one of the most common malignant tumors in the world, with a high incidence and a poor prognosis. The current treatment methods are limited, and novel treatment strategies are need...
Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study [0.03%]
三线使用达可替尼治疗T790M突变阳性或阴性的EGFR L858R突变非小细胞肺癌患者的回顾性研究
Qian Wang,Xiaoyan Yin,Kaikai Zhao et al.
Qian Wang et al.
Background: Management of non-small cell lung cancer (NSCLC) after acquired resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is an unmet clinical need with no consensu...
Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma [0.03%]
表皮生长因子受体第20号外显子插入突变型非小细胞肺癌的中枢神经系统病变模式及分子分型
Amanda Reyes,Isa Mambetsariev,Jeremy Fricke et al.
Amanda Reyes et al.
Background: Epidermal growth factor receptor exon 20 insertion mutations (EGFR ins20) constitute a distinct entity among EGFR mutations. Therefore, we aimed to characterize patterns of central nervous system (CNS) metasta...
Surgical strategy after neoadjuvant immunochemotherapy for central-type NSCLC: restaging-guided versus pre-treatment-guided decision-making [0.03%]
新辅助免疫化疗后中心型非小细胞肺癌的手术策略：再评估指导与既往治疗指导决策模式的效果比较
Shoucheng Feng,Yuheng Zhou,Weizhen Sun et al.
Shoucheng Feng et al.
Background: Effective neoadjuvant immunochemotherapy (nICT) can downstage central-type non-small cell lung cancer (NSCLC) and reopen previously obstructed bronchi, but surgical decisions are frequently still anchored to p...
Biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation for unresectable locally advanced non-small cell lung cancer: a real-world retrospective cohort study [0.03%]
局部晚期不可切除的非小细胞肺癌双周卡铂白蛋白紫杉醇联合同期放疗后序贯度伐利尤单抗巩固治疗：一项真实世界回顾性队列研究
Yasuhito Nunomura,Hisashi Tanaka,Shintaro Oyama et al.
Yasuhito Nunomura et al.
Background: Durvalumab consolidation following concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC). We previously reported the efficacy of biweekly carbo...